Last reviewed · How we verify
SSGJ-706
At a glance
| Generic name | SSGJ-706 |
|---|---|
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients (PHASE2)
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers (PHASE2)
- Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSGJ-706 CI brief — competitive landscape report
- SSGJ-706 updates RSS · CI watch RSS
- Shenyang Sunshine Pharmaceutical Co., LTD. portfolio CI